Axsome Therapeutics (AXSM) Raw Materials (2022 - 2026)

Axsome Therapeutics has disclosed Raw Materials across 5 years of filings, most recently posting $11.9 million for Q1 2026.

• Raw Materials for Q1 2026 came in at $11.9 million, up 2.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.9 million (up 2.81% YoY), and the FY2025 annual result was $10.4 million, up 8.76% from the prior year.
• Raw Materials came in at $11.9 million for Q1 2026 at Axsome Therapeutics, up from $10.4 million in the prior quarter.
• In the past five years, Raw Materials ranged from a high of $12.4 million in Q3 2025 to a low of $2.1 million in Q3 2022.
• The 5-year median for Raw Materials is $7.7 million (2024), against an average of $7.4 million.
• Across the five-year window, Raw Materials soared 123.78% in 2023 and grew 2.81% in 2026, its largest moves.
• Axsome Therapeutics' Raw Materials stood at $2.5 million in 2022, then soared by 123.78% to $5.5 million in 2023, then jumped by 72.41% to $9.5 million in 2024, then gained by 8.76% to $10.4 million in 2025, then increased by 14.26% to $11.9 million in 2026.
• The last three Raw Materials figures came in at $11.9 million (Q1 2026), $10.4 million (Q4 2025), and $12.4 million (Q3 2025), per Business Quant data.